| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $63,215 | 6 | 43 |
Sells | $431,271 | 8 | 57 |
| Germano Geno J | director | 2 | $30,545 | 0 | $0 | $30,545 |
| Frankel Stanley | director | 2 | $18,690 | 0 | $0 | $18,690 |
| Brown Melinda | director | 2 | $13,980 | 0 | $0 | $13,980 |
| Scimeca Dario | General Counsel and Secretary | 0 | $0 | 3 | $58,909 | $-58,909 |
| SMITH J. JEFFERSON | Chief Research Officer | 0 | $0 | 2 | $60,018 | $-60,018 |
| Kelly John Alexander | Chief Financial Officer | 0 | $0 | 3 | $101,057 | $-101,057 |
| Amoroso Michael | President and CEO | 0 | $0 | 3 | $246,183 | $-246,183 |
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and …
Over the last 12 months, insiders at Precision BioSciences, Inc. have bought $63,215 and sold $431,271 worth of Precision BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Precision BioSciences, Inc. have bought $115,527 and sold $231,400 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Germano Geno J (director) — $30,545. Frankel Stanley (director) — $18,690. Brown Melinda (director) — $13,980.
The last purchase of 1,000 shares for transaction amount of $6,000 was made by Frankel Stanley (director) on 2026‑09‑28.
| 2026-09-28 | Frankel Stanley | director | 1,000 0.0037% | $6.00 | $6,000 | +2.88% | ||
| 2026-09-25 | Germano Geno J | director | 2,609 0.0102% | $6.28 | $16,385 | +3.05% | ||
| 2026-09-25 | Brown Melinda | director | 1,135 0.0044% | $6.27 | $7,116 | +3.05% | ||
| 2026-02-18 | Sale | Amoroso Michael | President and CEO | 20,559 0.1547% | $3.84 | $78,947 | +81.04% | |
| 2026-02-18 | Sale | Kelly John Alexander | Chief Financial Officer | 8,149 0.0613% | $3.84 | $31,292 | +81.04% | |
| 2026-02-18 | Sale | SMITH J. JEFFERSON | Chief Research Officer | 4,925 0.0371% | $3.84 | $18,912 | +81.04% | |
| 2026-02-18 | Sale | Scimeca Dario | General Counsel and Secretary | 4,925 0.0371% | $3.84 | $18,912 | +81.04% | |
| 2026-01-22 | Sale | Amoroso Michael | President and CEO | 34,799 0.2576% | $4.17 | $145,112 | +62.12% | |
| 2026-01-21 | Sale | SMITH J. JEFFERSON | Chief Research Officer | 10,200 0.0773% | $4.03 | $41,106 | +71.45% | |
| 2026-01-21 | Sale | Kelly John Alexander | Chief Financial Officer | 15,213 0.1153% | $4.03 | $61,308 | +71.45% | |
| 2026-01-21 | Sale | Scimeca Dario | General Counsel and Secretary | 8,854 0.0671% | $4.03 | $35,682 | +71.45% | |
| 2025-12-16 | Germano Geno J | director | 3,000 0.0222% | $4.72 | $14,160 | +38.38% | ||
| 2025-12-16 | Frankel Stanley | director | 2,700 0.0199% | $4.70 | $12,690 | +38.38% | ||
| 2025-12-15 | Brown Melinda | director | 1,381 0.0108% | $4.97 | $6,864 | +38.96% | ||
| 2025-11-03 | Sale | Amoroso Michael | President and CEO | 3,409 0.023% | $6.49 | $22,124 | -11.68% | |
| 2025-11-03 | Sale | Kelly John Alexander | Chief Financial Officer | 1,303 0.0088% | $6.49 | $8,456 | -11.68% | |
| 2025-11-03 | Sale | Scimeca Dario | General Counsel and Secretary | 665 0.0045% | $6.49 | $4,316 | -11.68% | |
| 2025-09-26 | Frankel Stanley | director | 2,700 0.0225% | $4.97 | $13,419 | +28.66% | ||
| 2025-09-22 | Brown Melinda | director | 1,400 0.012% | $4.89 | $6,846 | +33.74% | ||
| 2025-07-03 | Sale | Kelly John Alexander | Chief Financial Officer | 14,827 0.131% | $4.26 | $63,163 | +16.71% |
| Kelly John Alexander | Chief Financial Officer | 125883 0.4561% | $877,404.51 | 8 | 4 | <0.0001% |
| Germano Geno J | director | 47492 0.1721% | $331,019.24 | 4 | 0 | +6.43% |
| Brown Melinda | director | 45481 0.1648% | $317,002.57 | 6 | 0 | +16.4% |
| Frankel Stanley | director | 41478 0.1503% | $289,101.66 | 3 | 0 | +28.66% |
| FMR LLC | 3738248 13.5436% | $26.06M | 1 | 0 | <0.0001% | |
| YAO TONY DUNG LING | director | 158003 0.5724% | $1.1M | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund, L.P. | director | 50000 0.1811% | $348,500.00 | 1 | 0 | <0.0001% |
| Buehler Kevin | director | 28137 0.1019% | $196,114.89 | 3 | 0 | +11.15% |
| Heery Christopher | Chief Medical Officer | 2485 0.009% | $17,320.45 | 1 | 0 | <0.0001% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 43 | +82.69% | 12M | +222.21% |
| Decreased Positions | 16 | -30.77% | 887,313 | -17.11% |
| New Positions | 21 | New | 9M | New |
| Sold Out Positions | 9 | Sold Out | 748,743 | Sold Out |
| Total Postitions | 79 | +51.92% | 16M | +205.1% |
| Bleichroeder Lp | $4,408.00 | 4.48% | 1.07M | 0 | 0% | 2025-09-30 |
| Lynx1 Capital Management Lp | $4,275.00 | 4.34% | 1.04M | +6,545 | +0.63% | 2025-09-30 |
| Aquilo Capital Management, Llc | $2,977.00 | 3.03% | 726,149 | +189,773 | +35.38% | 2025-03-31 |
| Tang Capital Management Llc | $2,680.00 | 2.72% | 653,649 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,020.00 | 2.05% | 492,596 | +87,242 | +21.52% | 2025-09-30 |
| Renaissance Technologies Llc | $804.00 | 0.82% | 196,177 | +115,900 | +144.38% | 2025-09-30 |
| Boothbay Fund Management, Llc | $732.00 | 0.74% | 178,535 | -21,465 | -10.73% | 2025-09-30 |
| Acadian Asset Management Llc | $489.00 | 0.5% | 119,359 | -106,578 | -47.17% | 2025-09-30 |
| Geode Capital Management, Llc | $449.00 | 0.46% | 109,521 | +31,809 | +40.93% | 2025-09-30 |
| Blackrock, Inc. | $405.00 | 0.41% | 98,699 | +41,209 | +71.68% | 2025-09-30 |